Assembly Biosciences
ASMB
44 hedge funds and large institutions have $7.09M invested in Assembly Biosciences in 2023 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 7 increasing their positions, 9 reducing their positions, and 4 closing their positions.
300% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 4
38% more funds holding
Funds holding: 32 → 44 (+12)
4.99% less ownership
Funds ownership: 18.13% → 13.14% (-5%)
22% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 9
40% less capital inflows, than outflows
Capital inflows: $1.42M | Capital outflows: $2.35M
60% less call options, than puts
Call options by funds: $2K | Put options by funds: $5K
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Anson Funds Management
Dallas,
Texas
|
+$570K |
| 2 |
AI
Acuitas Investments
Seattle,
Washington
|
+$210K |
| 3 |
Two Sigma Investments
New York
|
+$107K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$100K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$78.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
Alerce Investment Management
Chicago,
Illinois
|
-$1.97M |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$177K |
| 3 |
BlackRock
New York
|
-$90.9K |
| 4 |
Renaissance Technologies
New York
|
-$50.1K |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$29.4K |
ASMB Hedge Fund Activity: Q4 2023 in Review
44 of the 6,875 institutional investors tracked by Wall St. Rank reported a position in Assembly Biosciences (ASMB) for Q4 2023, worth a combined $7.09M — down 16% from $8.44M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new ASMB positions and 4 closed out — a net gain of 12 holders — while 7 added to existing stakes and 9 trimmed.
The largest buyer was Anson Funds Management, opening a new position worth an estimated $570K. The largest seller was Alerce Investment Management, exiting entirely with an estimated $1.97M sold.
- 44 institutional investors held Assembly Biosciences (ASMB) as of Q4 2023, up from 32 in Q3 2023.
- Funds reported $7.09M of Assembly Biosciences stock for Q4 2023, down 16% quarter-over-quarter.
- 16 funds opened new Assembly Biosciences positions in Q4 2023 and 4 closed out, a net change of +12 holders.
- The largest Assembly Biosciences buyer in Q4 2023 was Anson Funds Management, an estimated $570K added.
- The largest Assembly Biosciences seller in Q4 2023 was Alerce Investment Management, an estimated $1.97M sold.
Based on aggregated 13F filings for Q4 2023.